Downward price pressures on Humacyte shares are typically triggered by broader small-cap biotech market sell-offs, quarterly financial reports featuring wider-than-expected net losses, slower-than-anticipated initial commercial revenue growth, and concerns regarding cash burn. Additionally, clinical-stage companies frequently experience sharp pullbacks when capital raises or equity dilutions are executed to maintain operational liquidity.